LB Pharmaceuticals Inc (NASDAQ:LBRX) Financings

LB Pharmaceuticals Inc

Financings

RaiseDate
Private placement of common stock and pre-funded warrants
Announced: about US$150M · US$34.94 a share · Leerink Partners +1
Dealers: Leerink Partners, Piper Sandler
Buyers: Adage Capital Partners, L.P.; BB Biotech; Caligan Partners; Commodore Capital; Deep Track Capital; Farallon Capital Management; Integral Health Asset Management; Janus Henderson Investors; Spruce Street Capital; StemPoint Capital LP
Use of proceeds: Expand LB-102 into new indications such as negative symptoms of schizophrenia and Alzheimer's agitation/psychosis, plus working capital and general purposes
Jul 29, 2026
Private placement of common stock and pre-funded warrants
Announced: about US$100M · US$21.17 a share · Leerink Partners +2
Dealers: Leerink Partners, Piper Sandler, Stifel
Buyers: Balyasny Asset Management L.P.; Caligan Partners; Commodore Capital; Deep Track Capital; Nantahala Capital; Pivotal bioVenture Partners; Spruce Street Capital; TCGX; Trails Edge Capital Partners
Use of proceeds: Fund a Phase 2 trial of LB-102 as adjunctive treatment for major depressive disorder, plus working capital and general corporate purposes
Feb 5, 2026
Public offering of common stock
Announced: US$285M · US$15 a share · Leerink Partners +2
Dealers: Leerink Partners (co-lead), Piper Sandler (co-lead), Stifel (co-lead)
Sep 11, 2025

Read by 6ix AI from the company's releases